학술논문
Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.
Document Type
Article
Author
Shore, Neal D.; Clarke, Noel; Armstrong, Andrew J.; Oya, Mototsugu; Procopio, Giuseppe; Guedes, João Daniel Cardoso; Arslan, Cagatay; Mehra, Niven; Brown, Emma; Schlürmann, Friederike; Joung, Jae Young; Sugimoto, Mikio; Vianna, Karina; Hosius, Christian; Barnicle, Alan; Liu, Yu-Zhen; Harrington, Elizabeth; McGuinness, David; del Rosario, Paula Michelle; Saad, Fred
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p165-165, 235p
Subject
Language
ISSN
0732183X